Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEMTRADA vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Treatment of relapsing forms of multiple sclerosis (MS), for patients who have had an inadequate response to two or more drugs indicated for MS.,Treatment of B-cell chronic lymphocytic leukemia (B-CLL) (off-label in many regions due to regulatory changes).
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Alemtuzumab is a monoclonal antibody; it is not metabolized by cytochrome P450 enzymes. Clearance occurs via intracellular catabolism and proteolytic degradation.
Metabolized by exonucleases to shorter oligonucleotides.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Not determined; likely low due to monoclonal antibody nature (primarily binds to CD52 antigen).
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Approximately 0.1 L/kg; indicates limited extravascular distribution, primarily in serum and lymphoid tissues.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
IV only; not applicable (100% bioavailability via IV infusion).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Safety and efficacy in pediatric patients (<18 years) have not been established.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment recommended; limited data available in patients ≥65 years; use with caution due to higher risk of infections and immune-mediated disorders.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
WARNING: SERIOUS AUTOIMMUNE CONDITIONS, INFUSION REACTIONS, AND MALIGNANCIES. Alemtuzumab can cause serious, potentially fatal autoimmune conditions (e.g., immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, autoimmune pancytopenia), infusion reactions, and an increased risk of malignancies including thyroid cancer, melanoma, and lymphoproliferative disorders. Only prescribers enrolled in a restricted distribution program should prescribe alemtuzumab.
None.
Autoimmune conditions: Monitor for immune thrombocytopenia, glomerulonephropathies, autoimmune hemolytic anemia, and autoimmune pancytopenia.,Infusion reactions: Premedicate and monitor; reactions can be severe.,Infections: Increased risk due to lymphopenia; monitor for Listeria, herpes, and other opportunistic infections.,Malignancies: Monitor for thyroid cancer, melanoma, and lymphoproliferative disorders.,Vaccination: Avoid live vaccines during and after treatment.,Reproductive risk: Advise women of childbearing age to use contraception during and for 4 months after treatment.
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Hypersensitivity to alemtuzumab or any of its excipients.,Active infection (except minor localized infections).,Known history of progressive multifocal leukoencephalopathy (PML).,Concurrent treatment with other immunosuppressive therapies (not recommended).
Hypersensitivity to oblimersen or any component of the formulation
No specific food interactions. Grapefruit and other CYP450 substrates are not relevant; alemtuzumab is not metabolized by CYP enzymes. Avoid alcohol due to potential immune effects.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta. First trimester: Fetal Ig G exposure begins around week 13 of gestation; prior to that, transfer is minimal. Second and third trimesters: Ig G actively transported across placenta, increasing fetal exposure. Cases of fetal harm (spontaneous abortion, fetal death) reported. Risk of profound lymphopenia and other immune alterations in the newborn. No adequate human studies; animal studies show embryolethality and developmental toxicity.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
Excreted in human milk in low amounts; M/P ratio not available. Given the high molecular weight (approx. 150 k Da) and potential for immunosuppression in the nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
Contraindicated; do not use in pregnancy. No dosing adjustment studies exist. If a woman becomes pregnant during treatment, discontinue therapy immediately and refer to high-risk obstetrics. No pharmacokinetic data are available to suggest dose changes in pregnancy; however, altered volume of distribution and clearance may occur but are not characterized.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS). Administer via IV infusion over 4 hours for 5 consecutive days (first course) and 3 consecutive days (second course, 12 months later). Premedicate with corticosteroids (e.g., methylprednisolone 1 g IV) for 3 days each course to mitigate infusion reactions. Monitor for autoimmune adverse effects: immune thrombocytopenia (ITP), thyroid disorders, nephropathies. Obtain baseline and monthly CBC, serum creatinine, urinalysis with microscopy, and thyroid function for 48 months after last dose. Vaccinate for varicella zoster virus (VZV) at least 6 weeks prior if seronegative; avoid live vaccines during and after treatment. Pregnancy category C—contraindicated in pregnancy; effective contraception required during and 4 months after treatment.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
This drug is given as an intravenous infusion for five days in a row for the first course, and three days in a row one year later. Each infusion takes about 4 hours.,You will receive steroid medications before each infusion to reduce the risk of infusion reactions (fever, chills, rash, breathing problems).,Serious side effects include autoimmune conditions affecting blood cells (low platelets), thyroid, or kidneys. You need monthly blood and urine tests for at least four years after the last dose.,You may be at higher risk for infections; report any signs of infection (fever, cough, painful urination) immediately.,Do not receive live vaccines (e.g., chickenpox, nasal flu vaccine) during treatment and for at least 12 months after.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEMTRADA vs ANTHIM, answered by our medical review team.
LEMTRADA is a Monoclonal Antibody that works by Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEMTRADA and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEMTRADA is: 12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEMTRADA and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEMTRADA is classified as Category C. Pregnancy category: Contraindicated in pregnancy. Alemtuzumab is an IgG1 monoclonal antibody that crosses the placenta. First trimester: Fetal IgG exposure begins around week 13 of. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.